Chennai, July 2 (Ians) Around 65,087 sanitary workers of Tamil Nadu attended the medical camps for sanitary workers on Sunday.
The camp was inaugurated by Health Minister Ma Subramanian while the inaugural function was held at Government higher secondary school, Kodambakkam.
Ma Subramanian said that the camp for sanitary workers which was announced in the budget of 2022-23 has commenced.
“The camp would conduct master body checkups for the sanitary workers and the health department would provide medical treatment for those sanitary workers who were diagnosed with diseases,” the minister said.
The minister said that the medical colleges would provide treatment to the sanitary workers on the base of the reports from the health camps.
He said that the state public health department would have details of the patients and would set time table for the people on when and where they should go for full body check up.
The minister said that it includes X-Ray,...
The camp was inaugurated by Health Minister Ma Subramanian while the inaugural function was held at Government higher secondary school, Kodambakkam.
Ma Subramanian said that the camp for sanitary workers which was announced in the budget of 2022-23 has commenced.
“The camp would conduct master body checkups for the sanitary workers and the health department would provide medical treatment for those sanitary workers who were diagnosed with diseases,” the minister said.
The minister said that the medical colleges would provide treatment to the sanitary workers on the base of the reports from the health camps.
He said that the state public health department would have details of the patients and would set time table for the people on when and where they should go for full body check up.
The minister said that it includes X-Ray,...
- 7/2/2023
- by Agency News Desk
- GlamSham
Bengaluru, March 10 (Ians) Pharmaceutical company AstraZeneca India on Wednesday announced that it has received marketing approval for Tagrisso (Osimertinib) for adjuvant treatment after complete tumour resection in patients with non-small cell lung cancer (Nsclc), whose tumours have epidermal growth factor receptor (Egfr) mutations.
Osimertinib, a once daily oral pill, when given to patients of lung cancer whose tumour has a specific mutation called Egfr mutation and who have undergone surgical removal of the lung tumour, has shown to decrease the risk of cancer recurrence by nearly 83 per cent in the Adaura clinical trial in early stage lung cancer patients, the company said in a statement.
"AstraZeneca has always been and will continue to bring forward world-class treatment solutions for non-communicable diseases," said Gagandeep Singh Bedi, Managing Director, AstraZeneca India.
"The regulatory approval of Tagrisso (Osimertinib) in India will provide better medicine for the management of Non-Small Cell Lung Cancer and...
Osimertinib, a once daily oral pill, when given to patients of lung cancer whose tumour has a specific mutation called Egfr mutation and who have undergone surgical removal of the lung tumour, has shown to decrease the risk of cancer recurrence by nearly 83 per cent in the Adaura clinical trial in early stage lung cancer patients, the company said in a statement.
"AstraZeneca has always been and will continue to bring forward world-class treatment solutions for non-communicable diseases," said Gagandeep Singh Bedi, Managing Director, AstraZeneca India.
"The regulatory approval of Tagrisso (Osimertinib) in India will provide better medicine for the management of Non-Small Cell Lung Cancer and...
- 3/10/2021
- by Glamsham Bureau
- GlamSham
IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news articles, Tweets, and blog posts do not represent IMDb's opinions nor can we guarantee that the reporting therein is completely factual. Please visit the source responsible for the item in question to report any concerns you may have regarding content or accuracy.